title: [Clinical manifestations, diagnosis and course of Pneumocystis carinii pneumonia in patients with hematologic diseases].
abstract: OBJECTIVE
  To characterize clinical, diagnostic and course features of pneumonia caused by Pneumocystis carinii (PC) in hematologic inpatients.
  
  
  METHODS
  27 patients with blood diseases were studied. 22 of them had acute respiratory insufficiency and 5 had unclear lung affection. The data from bronchoalveolar lavage (BAL), lung biopsy, serum tests for IgG, IgM anti-PC-antibodies were used for diagnosis of PC-pneumonia.
  
  
  RESULTS
  PC-pneumonia was diagnosed in 8 of 27 patients. Clinical manifestations characteristic for PC-pneumonia were not found. In 5 patients the diagnosis was made on the evidence provided by BAL. Lymphocyte count in BAL was elevated to 27.7 +/- 8.7%. Open biopsy of the lung and transbronchial biopsy diagnosed PC-pneumonia in 2 and 1 patients, respectively. Previous BAL examinations failed to detect PC-pneumonia in 2 of them. In all the patients PC-pneumonia was associated with another infection (bacterial, cytomegaloviral). Histologically, the picture of the disease was determined by the severity of the lung affection or its complications. 5 of 8 patients failed treatment with trimethoprim-sulphamethoxazole and died. Marked respiratory insufficiency was registered at PC-pneumonia diagnosis in all the lethal cases.
  
  
  CONCLUSIONS
  Clinical and x-ray pictures of PC-pneumonia in hemoblastosis patients are not specific. All such patients with symptoms of lung infection resistant to antibacterial and antifungal therapy should be examined for PC-pneumonia.
authors.forename: G M
authors.initials: GM
authors.lastname: Galstian
authors.forename: V M
authors.initials: VM
authors.lastname: Gorodetskiĭ
authors.forename: L Iu
authors.initials: LIu
authors.lastname: Tikhonova
authors.forename: L L
authors.initials: LL
authors.lastname: Speranskaia
authors.forename: L N
authors.initials: LN
authors.lastname: Gotman
authors.forename: E E
authors.initials: EE
authors.lastname: Mirzoian
authors.forename: E N
authors.initials: EN
authors.lastname: Glasko
authors.forename: R G
authors.initials: RG
authors.lastname: Kuliev
authors.forename: T N
authors.initials: TN
authors.lastname: Rybalkina
authors.forename: L F
authors.initials: LF
authors.lastname: Evseeva
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D000741:Anemia, Aplastic / Q000150:complications; D000754:Anemia, Refractory, with Excess of Blasts / Q000150:complications; D000890:Anti-Infective Agents / Q000627:therapeutic use; D001706:Biopsy; D001992:Bronchoalveolar Lavage Fluid; D005260:Female; D006402:Hematologic Diseases / Q000150:complications*; D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications; D007951:Leukemia, Myeloid / Q000150:complications; D008168:Lung / Q000473:pathology; D008232:Lymphoproliferative Disorders / Q000150:complications*; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000150:complications; D011020:Pneumonia, Pneumocystis / Q000175:diagnosis* / Q000188:drug therapy / Q000473:pathology; D013902:Radiography, Thoracic; D012131:Respiratory Insufficiency / Q000209:etiology; D014057:Tomography, X-Ray Computed; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000627:therapeutic use
chemical_list: D000890:Anti-Infective Agents; D015662:Trimethoprim, Sulfamethoxazole Drug Combination